PDCD1 and head and neck squamous cell carcinoma: Our retrospective real-world study firstly reported the efficacy and safety of cetuximab with PD-1 immunotherapy salvage therapy in patients with R/M HNSCC that were refractory to the PD-1 immunotherapy.